Summary:
The TRAVERSE trial, a landmark FDA-mandated study involving over 5,200 men, has definitively concluded that testosterone replacement therapy (TRT) does not increase the risk of major cardiovascular events like heart attacks, strokes, or cardiovascular death when administered at...